These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 24123173)

  • 1. Drug-induced removal of nitrogen derivatives in urine: a new concept whose time has come.
    Córdoba J; Ventura-Cots M
    Hepatology; 2014 Mar; 59(3):764-6. PubMed ID: 24123173
    [No Abstract]   [Full Text] [Related]  

  • 2. New strategies for treating hepatic encephalopathy.
    Gómez-Gutiérrez C; Manzano-Robleda MC; Uribe M; Méndez-Sánchez N
    Ann Hepatol; 2014; 13(3):409-11. PubMed ID: 24756021
    [No Abstract]   [Full Text] [Related]  

  • 3. Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy.
    Rockey DC; Vierling JM; Mantry P; Ghabril M; Brown RS; Alexeeva O; Zupanets IA; Grinevich V; Baranovsky A; Dudar L; Fadieienko G; Kharchenko N; Klaryts'ka I; Morozov V; Grewal P; McCashland T; Reddy KG; Reddy KR; Syplyviy V; Bass NM; Dickinson K; Norris C; Coakley D; Mokhtarani M; Scharschmidt BF;
    Hepatology; 2014 Mar; 59(3):1073-83. PubMed ID: 23847109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of hyperammonemia in liver failure.
    Jover-Cobos M; Khetan V; Jalan R
    Curr Opin Clin Nutr Metab Care; 2014 Jan; 17(1):105-10. PubMed ID: 24281376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. L-Ornithine phenylacetate (OP): a novel treatment for hyperammonemia and hepatic encephalopathy.
    Jalan R; Wright G; Davies NA; Hodges SJ
    Med Hypotheses; 2007; 69(5):1064-9. PubMed ID: 17467190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacotherapy for hyperammonemia.
    Hadjihambi A; Khetan V; Jalan R
    Expert Opin Pharmacother; 2014 Aug; 15(12):1685-95. PubMed ID: 25032885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycine and hyperammonemia: potential target for the treatment of hepatic encephalopathy.
    Kristiansen RG; Rose CF; Ytrebø LM
    Metab Brain Dis; 2016 Dec; 31(6):1269-1273. PubMed ID: 27339764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interorgan ammonia metabolism in liver failure: the basis of current and future therapies.
    Wright G; Noiret L; Olde Damink SW; Jalan R
    Liver Int; 2011 Feb; 31(2):163-75. PubMed ID: 20673233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycerol phenylbutyrate efficacy and safety from an open label study in pediatric patients under 2 months of age with urea cycle disorders.
    Longo N; Diaz GA; Lichter-Konecki U; Schulze A; Inbar-Feigenberg M; Conway RL; Bannick AA; McCandless SE; Zori R; Hainline B; Ah Mew N; Canavan C; Vescio T; Kok T; Porter MH; Berry SA
    Mol Genet Metab; 2021 Jan; 132(1):19-26. PubMed ID: 33388234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current state of knowledge of hepatic encephalopathy (part I): newer treatment strategies for hyperammonemia in liver failure.
    Kristiansen RG
    Metab Brain Dis; 2016 Dec; 31(6):1357-1358. PubMed ID: 27651377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel Ammonia-Lowering Agents for Hepatic Encephalopathy.
    Rahimi RS; Rockey DC
    Clin Liver Dis; 2015 Aug; 19(3):539-49. PubMed ID: 26195207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ammonia-lowering strategies for the treatment of hepatic encephalopathy.
    Rose CF
    Clin Pharmacol Ther; 2012 Sep; 92(3):321-31. PubMed ID: 22871998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treating hepatic encephalopathy in cirrhotic patients admitted to ICU with sodium phenylbutyrate: a preliminary study.
    Weiss N; Tripon S; Lodey M; Guiller E; Junot H; Monneret D; Mayaux J; Brisson H; Mallet M; Rudler M; Imbert-Bismut F; Thabut D;
    Fundam Clin Pharmacol; 2018 Apr; 32(2):209-215. PubMed ID: 29239015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic encephalopathy: an enigma from patient to enzyme and back.
    Vilstrup H; Schousboe A
    Metab Brain Dis; 2013 Jun; 28(2):117. PubMed ID: 23417286
    [No Abstract]   [Full Text] [Related]  

  • 15. Role of branched chain amino acids in cerebral ammonia homeostasis related to hepatic encephalopathy.
    Bak LK; Waagepetersen HS; Sørensen M; Ott P; Vilstrup H; Keiding S; Schousboe A
    Metab Brain Dis; 2013 Jun; 28(2):209-15. PubMed ID: 23371316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Taurine treatment preserves brain and liver mitochondrial function in a rat model of fulminant hepatic failure and hyperammonemia.
    Jamshidzadeh A; Heidari R; Abasvali M; Zarei M; Ommati MM; Abdoli N; Khodaei F; Yeganeh Y; Jafari F; Zarei A; Latifpour Z; Mardani E; Azarpira N; Asadi B; Najibi A
    Biomed Pharmacother; 2017 Feb; 86():514-520. PubMed ID: 28024286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of ammonia and inflammation in minimal hepatic encephalopathy.
    Shawcross DL; Wright G; Olde Damink SW; Jalan R
    Metab Brain Dis; 2007 Mar; 22(1):125-38. PubMed ID: 17260161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ornithine phenylacetate revisited.
    Jover-Cobos M; Noiret L; Sharifi Y; Jalan R
    Metab Brain Dis; 2013 Jun; 28(2):327-31. PubMed ID: 23456516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical science workshop: targeting the gut-liver-brain axis.
    Patel VC; White H; Støy S; Bajaj JS; Shawcross DL
    Metab Brain Dis; 2016 Dec; 31(6):1327-1337. PubMed ID: 26446022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperammonemic hepatic encephalopathy management through L-ornithin-L-aspartate administration in dogs.
    Ahn JO; Li Q; Lee YH; Han SM; Hwang CY; Youn HY; Chung JY
    J Vet Sci; 2016 Sep; 17(3):431-3. PubMed ID: 26726023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.